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Abstract
Background: Vitamin D binding protein-macrophage activating factor (DBP-maf) is a potent inhibitor of tumor growth. Its
activity, however, has been attributed to indirect mechanisms such as boosting the immune response by activating
macrophages and inhibiting the blood vessel growth necessary for the growth of tumors.
Methods and Findings: In this study we show for the first time that DBP-maf exhibits a direct and potent effect on prostate
tumor cells in the absence of macrophages. DBP-maf demonstrated inhibitory activity in proliferation studies of both LNCaP
and PC3 prostate cancer cell lines as well as metastatic clones of these cells. Flow cytometry studies with annexin V and
propidium iodide showed that this inhibitory activity is not due to apoptosis or cell death. DBP-maf also had the ability to
inhibit migration of prostate cancer cells in vitro. Finally, DBP-maf was shown to cause a reduction in urokinase plasminogen
activator receptor (uPAR) expression in prostate tumor cells. There is evidence that activation of this receptor correlates with
tumor metastasis.
Conclusions: These studies show strong inhibitory activity of DBP-maf on prostate tumor cells independent of its
macrophage activation.
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Introduction
Vitamin D binding protein (DBP) is the main transporter of
vitamin D in the bloodstream. It has a molecular weight between
52–59 kDa and is found in the bloodstream at a level between
300–600 mg/mL [1,2]. DBP is the parent molecule of DBP-maf
[3]. DBP-maf is the product of selective deglycosylation of DBP
and has been shown to be a potent antiangiogenic and
antitumorigenic molecule [4–6]. We have demonstrated previous-
ly in a xenograft mouse model that DBP-maf is a potent inhibitor
of human pancreatic tumors and that its ability to inhibit tumor
growth in vivo is due, in part, to its antiangiogenic properties [4]. In
that study it was shown that DBP-maf is antiangiogenic based on
the reduction of vessels in the chick chorioallantoic membrane,
and based on reduced microvessel density in tumors. It has been
suggested in other studies that its primary antitumor mechanisms
are immunological, due to its activation of macrophages. Recent
clinical studies by Yamamoto et al have shown potent anti-tumor
activity, as well as activity against HIV [7–10]. This activity was
measured as a function of reduced serum levels of the enzyme
a-N-acetylgalactosaminidase (nagalase). Nagalase deglycosylation
of DBP prevents it from activating macrophages and therefore
suppresses the immune response [11]. The basic mechanism
proposed in all cases is largely the activation of macrophages and
the ensuing immune responses. In HIV it has been suggested that
defective antigen presentation is a factor in immune deficiency
[12]. The presence of elevated nagalase in the plasma of HIV
patients suggests that macrophage activation may be inhibited in
these patients [13]. In addition, nagalase has been shown to be an
intrinsic component of an envelope protein promoting fusion for
the initiation of infection [11]. The plasma concentration of
nagalase in patients with systemic lupus erythematosus was also
found to be elevated. In lupus, autoantibodies form pathogenic
immune complexes and are deposited in tissues. The clearance of
these complexes by macrophages is inhibited if macrophage
activation is disrupted [14]. Cancer cells have been shown to
produce nagalase [15] and elevated concentrations in serum have
been recorded in a number of cancer patients suffering from
melanoma [16], prostate, colorectal, and metastatic breast cancer
[7–9]. A thorough understanding of DBP-maf activity is yet to be
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13428attained, but its potential as an antiangiogenic and immunogenic
therapy is clear.
Four prostate cancer cell lines were used in this study in
order to include; the androgen sensitive (LNCaP) and
insensitive (PC3M) lines, as well as highly metastatic lines
(LNCaPLN3 and PC3MLN4) derived from each parental line,
respectively.
The ability of DBP-maf to have a direct effect on tumor cells has
not been reported. This study investigated the role of DBP-maf in
direct inhibition of activities such as proliferation, migration, and
expression of uPAR that are related to tumor growth and
metastasis.
Materials and Methods
Synthesis of DBP-maf
(a) Preparation of (1-3)b-D-galactosidase-agarose beads.
Preparation of beads was done using a modification of the method
of Yamamoto et al [17]. Cyanogen bromide-activated beads (0.5 g)
were washed with 1 mM HCl (3X, 10 mL per wash) using suction
filtration. The beads were then washed with DDI water and
resuspended in 2 mL of coupling buffer (0.1 M NaHCO3, 0.5 M
NaCl, pH 8.3). (1-3)b-D-galactosidase (1000 units) was added to the
beads/coupling buffer and then shaken with an over and under
mixer for 2 hours at room temperature. The beads were then
washed with coupling buffer and resuspended in blocking buffer
(coupling buffer plus 0.2 M glycine). The suspension was shaken
overnight at 4uC. The beads were then washed with coupling buffer
followed by 0.1 M sodium acetate, 0.5 M NaCl, pH 4.0, and the
washes were repeated for a total of four times. The beads were
washed with a final wash of coupling buffer then spun down and
resuspended in 1.0 M NaCl.
(b) Determination of (1-3)b-D-galactosidase-agarose bead
activity. Determination of bead activity was done using a
modification of the method of Yamamoto et al [17]. In order to
determine the activity of the (1-3)b-D-galactosidase-agarose beads,
50 mL of the bead suspension were added to 0.95 mL of assay
buffer/chromogenic substrate (PBS, 3 mM 2-nitrophenyl-b-D-
galactopyranoside, 10 mM MgCl2, 0.1 mM b-mercaptoethanol),
and the suspension was shaken at room temperature for 15 min.
The reaction was stopped with 33 mLo f1Ms o d i u mc a r b o n a t e ,
and the absorbance was measured at 405 nm. Activity was
expressed as units/mL of bead suspension, where 1 unit is
defined as the number of mmol of p-nitrophenol formed per
minute. A molar absorbtivity of 18380 L/mol cm, and a path
length of 0.25 cm corresponding to a 200 mL volume in a 96-
well plate were used to calculate the concentration of p-
nitrophenol.
(c) Deglycosylation of DBP with (1-3)b-D-galactosidase-
agarose beads. Deglycosylation of DBP was done using a
modification of the method of Yamamoto et al [17]. DBP
Figure 1. DBP-maf inhibits tumor cell migration. LNCaP (A), LNCaPLN3 (B), PC3M (C) or PC3MLN4 (D) cells were added (150,000/well) to the
top chamber of a modified Boyden chamber (+/2 DBP-maf) with 10% FBS in the bottom chamber. After 6 hours cells were removed that had not
migrated and remaining cells were quantitated using an acid phosphatase assay. Results were normalized to control. Experiments were performed a
minimum of three times and error is shown as +/2 SD. Compared to cell growth without DBP-maf, adding DBP-maf had a statistically significant
overall reduction of cell migration at 30% (P=0.0003) for the combined four tumor cell types. Individual significant reduction rates were found with
each of these tumor cell types. Compared to control, significant reduction was seen with DBP-maf at (A) 20% P=0.0022 (B) 20% P=0.0029 (C) 10%
P=.0045 (D) 30% P=.0094. n=3.
doi:10.1371/journal.pone.0013428.g001
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of 0.05 mg/mL in PBS pH 6.0, 10 mM MgCl2, with 0.007 U of
(1-3) b-D-galactosidase-agarose and 0.004 U of neuraminidase-
agarose (Sigma, St. Louis), and shaken at room temperature for
4 hours. The total reaction volume was 1 mL. The beads were
then sedimented by centrifugation and removed. DBP-maf was
stored in aliquots at 220uC.
DBP-maf peptide
A 14 amino acid DBP-maf peptide was synthesized (Ana Spec,
Fremont,CA) with the amino acid sequence: Ac-TPTE-
LAKLVNKRSE. Purity was .90%.
Cell culture
PC3M, PC3MLN4, LNCaP, and LNCaPLN3 cells were kindly
provided by Dr. Curtis Pettaway and Dr. Isaiah J. Fidler (M. D.
Anderson Cancer Center). The PC3M cell line was isolated from
liver metastases produced in nude mice subsequent to intrasplenic
injection of the androgen-insensitive PC3 human prostate
carcinoma cell line [18]. The metastatic sublines, PC3MLN
and LNCaPLN, were created by injecting the parental cells
orthotopically into the dorsal lobe of the prostate of nude mice
and culturing the cells that had metastasized to the sentinel
(paraaortic) lymph node. After culture for 3–5 passages, these
cells were re-injected into the prostate of subsequent nude mice.
This process was repeated for 3 cycles to create the metastatic
line, LNCaPLN3 and for four cycles to create the metastatic line,
PC3MLN4 [18]. All tumor cells were cultured in RPMI 1640
(Invitrogen) with 10% fetal bovine serum (FBS), penicillin
(100 U/mL)/streptomycin (100 mg/mL), and L-glutamine and
incubated at 37uC, 10% CO2.
Acid phosphatase colorimetric assay
At the conclusion of each experiment, cells were washed in
PBS then 450 mL of acid phosphatase buffer (10 mM p-
nitrophenol phosphate, 0.1 M sodium acetate, 0.1% Triton X-
100, pH 5.8) were added to each well. Cells were incubated at
37uC for 45 minutes. Fifty ml of 1 N NaOH were added to each
well to stop the reaction and absorbance was measured at
405 nm [19,20]. Cell number of each cell type was calibrated
with absorbance using a hemacytometer to ensure that acid
phosphatase levels correlated in a linear fashion with cell number.
Analyses and plotting for all assays were done using Origin Pro 8
(Northampton, MA).
Figure 2. A DBP-maf peptide inhibits tumor cell migration. LNCaP (A), LNCaPLN3 (B), PC3M (C) or PC3MLN4 (D) cells were added (150,000/
well) to the top chamber of a modified Boyden chamber (+/2 DBP-maf) with 10% FBS in the bottom chamber. After 6 hours cells were removed that
had not migrated and remaining cells were quantitated using an acid phosphatase assay. Results were normalized to control. Experiments were
performed a minimum of three times and error is shown as +/2 SD. Compared to migration without DBP-maf, adding DBP-maf had a statistically
significant reduction of migration at 40% (P,0.0001) for the combination of all four tumor cell types. Individual significant reduction rates were
found with each of these tumor cell types. Compared to control, significant reduction was seen with DBP-maf at (A) 30% P=0.0038 (B) 40%
P=0.0016 (C) 20% P=.0038 (D) 40% P=.0005. n=3.
doi:10.1371/journal.pone.0013428.g002
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Migration assays were performed using a modified Boyden
chamber Millicell culture inserts (Millipore, Billerica, MA) with
8 mm pores [20–22]. Upper membranes were pre-incubated
overnight with fibronectin (10 mg/mL in PBS), which was
aspirated from wells the following morning. Cells (150,000 cells/
well) were plated in basal medium with.010% gelatin with or
without DBP-maf or DBP. Some sample wells were stained at the
completion of the incubation period to ensure that cell adhesion
on the upper membranes was uniform under all conditions. Basal
medium was added to bottom wells with or without 10% FBS.
Cells were incubated for six hours at 37uC, 10% CO2. Cells that
did not migrate were removed from the top of the membrane and
the migrated cells were quantitated using an acid phosphatase
colorimetric assay.
Proliferation assays
Tumor cells were maintained in RPMI 1640 (Invitrogen) with
10% FBS, penicillin/streptomycin, and L-glutamine and incubat-
ed at 37uC, 10% CO2. Cells were trypsinized and added to 24 well
plates (5,000 cells/well) in 0.5 mL of culture medium. Cells were
serum-starved overnight then medium was replaced with RPMI
1640, 1% FBS, penicillin/streptomycin and L-glutamine and
incubated for 72 hours with or without DBP-maf or DBP [23].
Cell proliferation was assessed using an acid phosphatase
colorimetric assay [4,23].
Flow cytometry
Cells were grown to ,80% confluence in 100 mm
2 dishes. Cells
were treated with or without DBP-maf (1 mg/mL) and incubated
at 37uC for 48 hours. Cells were trypsinized, centrifuged,
aliquoted into tubes and labeled with annexin V and propidium
iodide using an apoptosis detection kit (APOAF, Sigma, St. Louis,
MO). Annexin V and PI staining were performed following the
manufacturer’s recommendations. Flow cytometry analysis was
performed using a Cytomation MoFlo cell sorter following the
manufacturer’s recommendations.
Reverse transcription and real-time quantitative
polymerase chain reaction (RTQPCR)
Total RNA was extracted from human cells using Trizol reagent
(Invitrogen) according to manufacturer’s recommendations and
were treated with RNase-free DNase (Ambion). RNA integrity and
Figure 3. DBP-maf inhibits tumor cell proliferation. LNCaP (A), LNCaPLN3 (B), PC3M (C) or PC3MLN4 (D) cells were seeded in 24 well dishes
overnight, then medium +/2 DBP-maf was added with 1% FBS. After 72 hours cells were quantitated using an acid phosphatase assay. Results were
normalized to control. Experiments were performed a minimum of three times and error is shown as +/2 SD. Compared to control, significant
reduction was seen with DBP-maf at (A) 50% P=0.0001 (B) 50% P=0.0001 (C) no significant reduction (D) 40% P=.0073. n=3.
doi:10.1371/journal.pone.0013428.g003
Table 1. FACS analysis of apoptosis or necrosis.
Tumor cell type Apoptotic or necrotic cells (%) P-value
LNCaP 32 ,0.0001
+ DBP-maf 18
LNCaPLN3 30 ,0.0001
+ DBP-maf 21
PC3M 15 ,0.0001
+ DBP-maf 23
PC3M Ln4 31 ,0.0001
+ DBP-maf 6
Cells were treated with or without 1 mg/mL DBP-maf for 48 hours, propidium
iodide and annexin V were added and cells were analyzed using flow cytometry.
Results are representative of three experiments.
doi:10.1371/journal.pone.0013428.t001
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concentrations were determined spectrophotometrically (Nano-
Drop 1000 Spectrophotometer V3.7, ThermoFisher Scientific).
Total RNA (1 mg) was reverse transcribed as previously described
[24] using qScript cDNA SuperMix (Quanta Biosciences). The RT
products (cDNA) were amplified by real-time quantitative PCR
(Applied Biosystems 7900 HT Fast Real-Time PCR system) with
Power SYBR green Master Mix. Oligonucleotide primers specific
for human uPAR variant 1 (Genebank accession nu NM-002659,
forward 59- CAACGAGGGCCCAATCCT -39 and reverse 59-
GTAACACTGGCGGCCATTCT -39), uPAR variant 2
(Genebank accession nu NM-001005376, forward 59- CAAC-
GAGGGCCCAATCCT -39 and reverse 59- CACTGGCGGC-
CATTCTG -39), uPAR variant 3 (Genebank accession nu
NM-001005377, forward 59- GCCGTTACCTCGAATGCATT -
39 and reverse 59- GGCCCCTCTCACAGCTCAT -39), and 18S
rRNA (forward 59-CGCAGCTAGGAATAATGGAATAGG-39
and reverse 59-GCCTCAGTTCCGAAAACCAA-39) were used.
The QPCR cycling conditions were 50uC for 2 min, 95uC for
10 min followed by 40 cycles of a two-step amplification program
(95uC for 15 s and 58uC for 1 min). At the end of the amplification,
melting curve analysis was applied using the dissociation protocol
from the Sequence Detection system to exclude contamination with
unspecific PCR products. The PCR products were also confirmed
by agarose gel and showed only one specific band of the predicted
size. For negative controls, no RT products were used as templates
in the QPCR and no band was detected on the gel.
Relative expressions of target genes were determined by the
2
2DDCt method [25]. The untreated cells were chosen as the
calibrators.
Immunoblotting
Immunoblotting was performed using a modification of the
method of Besch et al [26]. Cells were cultured in 100 mm
2 dishes
and grown to ,80% confluence then serum-starved overnight.
Medium was replaced with RPMI (1% FBS). DBP or DBP-maf
was added at indicated concentrations. Cells were incubated for 24
or 72 hours at 37uC then lysed using HTG buffer (20 mM
HEPES, pH 7.4,10% glycerol, 1% Triton X-100) and harvested
using a cell scraper. Phenylmethanesulphonylfluoride (PMSF) was
added (100 mM). Lysates were separated using SDS-PAGE. Lanes
were normalized using equal protein loading (40 mg/lane). Protein
levels were determined using a BCA assay (Pierce, Rockford, IL).
Bands were transferred to a PVDF membrane. The membrane
was blocked overnight in 10% powdered non-fat milk and 0.10%
Tween 20 in PBS. The membrane was hybridized with an anti
uPAR antibody (Santa Cruz, CA), followed by hybridization with
a horseradish peroxidase-linked secondary antibody and visualized
using chemiluminescence. Vinculin was used as a loading control.
Statistical analysis
The effect of DBP-maf was tested separately for cell migration
and proliferation assays. A one sided t-test was used to measure the
statistical significance of reductions of tumor growth at various
levels. A two-sided Z-test was used to measure the effect of DBP-
maf in apoptosis or necrosis. All analyses were done using SAS
Statistical software version 9.1 (SAS Institute, Cary, North
Carolina) and a P-value #0.01 was used to identify statistical
significance.
Results
DBP-maf inhibits the migration of tumor cells
Invasion and migration of tumor cells are important steps in
tumor growth and metastasis. DBP-maf was tested for its effect on
cell migration in four tumor lines- two parental prostate cancer
lines (LNCaP and PC3M) and two metastatic clones of these lines
(LNCaPLN3 and PC3MLN4), using a modified Boyden chamber.
The basal level of migration between each parental line and its
respective metastatic clone remained unchanged. At all doses
tested, inhibition of migration was observed (Figure 1).
A DBP-maf peptide inhibits tumor cell migration
The preparation of DBP-maf involves multi-step enzymatic
processes. The selective deglycosylation is a necessary step in the
process because expression of DBP-maf in E. coli produced a protein
with no activity [4]. An active but more easily formulated version of
the molecule would make the manufacture of DBP-maf easier and
less expensive. For these reasons a DBP-maf peptide was synthesized
using a sequence from the parent molecule that had shown activity in
other studies [27]. The peptide was tested to determine its potential to
inhibit tumor cell migration. As shown in Figure 2, the peptide
showed significant ability to inhibit the migration of all tumor lines.
The inhibitory effect did not increase at higher doses, suggesting its
IC50 was lower than the dose range tested.
DBP-maf inhibits tumor cell proliferation
The four cell lines were then tested to determine their sensitivity
to DBP-maf in proliferation studies. As shown in Figure 3A, DBP-
maf at 1 mg/mL reduced proliferation to baseline levels or below
in all cell lines with the exception of PC3M. It was interesting that,
although the PC3M cells were not sensitive to DBP-maf in this
assay, the metastatic clone PC3MLN4 had developed sensitivity to
it.
At 1 mg/mL, DBP-maf had a statistically significant reduction of
cell growth at 40% (P=0.0073) for the combination of all tumor
cell types. Individual significant reduction rates (without DBP-maf
vs.1 mg/mL) were also found among these tumor cell types except
PC3M in which no significant reduction was found (Figure 3).
Proliferation studies using the DBP-maf peptide showed no
reduction in proliferation with any of the cell lines (data not
shown). This suggests that the ability to inhibit migration and
proliferation may reside in distinct areas of the protein and that
this peptide sequence may have no role in inhibiting proliferation.
It is also possible that the site responsible for full DBP-maf activity
is more complex and requires the selectively deglycosylated
sequence of the protein to be present.
In order to determine whether the inhibition of tumor cell
proliferation was due to cell death or apoptosis, flow cytometry
analysis was done using propidium iodide and annexin V
markers. These studies showed no evidence of either significant
cell death or toxicity resulting from DBP-maf treated cells
(Table 1) and, with the exception of the PC3M parental line,
showed a reduction.
RT-PCR shows reduction of uPAR expression in cells
treated with DBP-maf
The expression of urokinase plasminogen activator receptor
(uPAR) has been shown to correlate with increased metastasis in
Figure 4. DBP-maf inhibits expression of uPAR in LNCaPLN3 cells. LNCaP and LNCaPLN3, cells were treated with DBP or DBP-maf (0.001 and
1 mg/mL) and incubated for 24 hours then harvested. RT products (cDNA), identified as uPAR1, 2, and 3, were amplified by real-time quantitative PCR.
doi:10.1371/journal.pone.0013428.g004
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[32]). RT-PCR was performed on all cell types using three known
isoforms of uPAR precursors, including the soluble receptor,
isoform 2 (see Methods). As shown in Figure 4D, reduced RNA
expression was observed for LNCaPLN3 in the presence of DBP-
maf at both 0.001 and 1 mg/mL of DBP-maf for both uPAR1 and
uPAR2 isoforms. The isoforms uPAR2 and uPAR3 showed
similar reduction of expression with DBP-maf treatment of PC3M
cells. Interestingly, although PC3MLN4 cells showed no signifi-
cant response to DBP-maf (Figure 5D), there was a statistically
significant reduction of uPAR2 with DBP at 1 mg/mL. In almost
all conditions examined, after 72 hours uPAR levels had returned
to control values (data not shown). The peptide was also tested
using the cell line (LNCaPLN3), which was active in all assays and
(PC3M), which was active in migration but not in proliferation.
They showed no significant change in any of the uPAR isoform
levels with the peptide (Figure 6A and 6B). The tumor lines were
then tested to observe the effect of DBP-maf on uPAR expression
at the protein level. Cells were harvested after 24 hours and lysates
were immunoblotted. As shown in Figure 4, DBP-maf did not
inhibit the expression of uPAR in any cell lines after 24 hours
(Figure 7A), however a reduction was seen after 72 hours only in
the LNCaPLN3 cells (Figure 7B). DBP treated cells showed no
significant change in receptor expression.
Discussion
The vitamin D binding protein DBP-maf, has been shown to
inhibit both tumor and blood vessel growth. We demonstrate here,
for the first time, a direct effect on prostate cancer cells in the
absence of macrophages, increasing the scope of DBP-maf beyond
its already demonstrated antiangiogenic and immuno-modulatory
Figure 5. DBP-maf inhibits expression of uPAR in PC3M cells. PC3M, and PC3MLN4 cells were treated with DBP or DBP-maf (0.001 and 1 mg/
mL) and incubated for 24 hours then harvested. RT products (cDNA), identified as uPAR1, 2, and 3, were amplified by real-time quantitative PCR.
p,0.05.
doi:10.1371/journal.pone.0013428.g005
Figure 6. DBP-maf peptide does not inhibit expression of uPAR in PC3M or LNCaPLN3 cells. LNCaPLN3 (A) and PC3M cells (B) were
treated with DBP or DBP-maf (0.001 and 1 mg/mL) and incubated for 24 hours then harvested. RT products (cDNA), identified as uPAR1, 2, and 3, were
amplified by real-time quantitative PCR. p,0.05.
doi:10.1371/journal.pone.0013428.g006
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proliferation and migration of tumor cells.
It is interesting to note the response of the parental PC3M cells
compared to the metastatic clone. PC3M cells did not show
sensitivity to DBP-maf in proliferation assays, but their migration
was inhibited by DBP-maf. There was a reduction of uPAR
expression as detected by RT-PCR, but protein expression of the
uPAR isotypes tested appeared unchanged. Finally, DBP-maf
caused a slight increase in loss due to apoptosis or necrosis (Table 1),
whereas the other cell lines demonstrated decreased apoptosis or
necrosis. The metastatic clone PC3MLN4 exhibited a potent
response to treatment in both proliferation and migration even at
low dose (1 ng/mL) but showed no reduction in uPAR expression
either at the mRNAor protein level.Additional proliferationstudies
were done to determine whether the discrepancy in response
between the parental and metastatic clone was due to a general
change in cell sensitivity. Calcitriol showed potent and consistent
inhibition among all cell types within identical dose ranges. PC3M
and PC3MLN4 cells were also tested with etoposide and their
responses were similar (data not shown), suggesting that the
metastatic clone gained sensitivity to DBP-maf that the parental
line does not demonstrate. The effect of DBP-maf on PC3MLN4
cells caused the highest significant reduction rates of proliferation
and migration compared to the other cell lines. Studies showed all
tumor cell lines to be sensitive to DBP-maf in migration assays.
Our observations in culturing of these cells were that the
metastatic clones of both PC3M and LNCaP were more sensitive
to trypsinization than the parental lines. Many factors may
regulate the migration of cells and although uPAR is a possible
mediator, it may not be the sole mechanism by which DBP-maf
inhibits migration. The peptide was effective in migration studies
but showed no ability to affect proliferation or uPAR expression.
Since the peptide represents only a portion of the protein it does
not possess all of the domains of the native DBP-maf, such as the
vitamin D binding region. It is possible that the ability to regulate
migration and proliferation resides in separate domains of the
protein. Although all of the cell lines responded to DBP-maf in one
or more of the assays, only LNCaPLN3 demonstrated reduction of
the uPAR protein level. It is possible, however, that the antibody
does not recognize all isoforms of uPAR.
It is now commonly accepted that the tumor microenviron-
ment, and not just the tumor cell alone, represents an effective
target for therapy. In addition to the investigation of anti-tumor
effects, the method of delivery of these drugs is being explored.
Figure 7. DBP-maf inhibits protein expression of uPAR. LNCaP, LNCaPLN3, PC3M, and PC3MLN4 were treated with DBP or DBP-maf and
incubated for 24 hours (A) then harvested and immunoblotted using an anti-uPAR antibody. LnCaPLN3 cells at 72 hours (B). p,0.05.
doi:10.1371/journal.pone.0013428.g007
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s t r a t e g y .P o o ra b s o r p t i o n ,i n t e r n a l i z a t i o n ,s h o r th a l f - l i f ei n
circulation, and a number of other deficiencies can make a
therapy that has shown great promise in vitro, ineffective in the
clinic. The effective in vivo doses for DBP-maf (pg-ng) have
tended to be lower than the in vitro doses (ng-mg range) [4,6–10].
P e r h a p st h i si sb e c a u s eo fm u l t i p le mechanisms of its activity.
The potential to impact blood vessel growth and tumor cell
growth as well as stimulate a potent immune response through
macrophage activation is difficult to measure in toto using in vitro
approaches. They do, however, provide a way to characterize
these effects individually.
The effect of DBP-maf treatment on uPAR expression in
prostate tumor cells was previously unknown. uPAR expression
has been correlated with tumor metastasis in a number of tumors
[26,28–30,32]. Studies of esophageal tumors showed PAI-1 and
uPA were expressed throughout the tumors but not in normal
esophageal tissue and that uPAR was expressed at the tumor
borders [33,34]. A link between pancreatic cancer and uPA has
been demonstrated, which could explain the potent effect of DBP-
maf in our previous pancreatic tumor studies [33].
The relationship among the plasmin-related proteins PAI-1,
uPA and uPAR is complex [35]. Although PAI-1 inhibits the
expression of uPA, which would be thought to inhibit tumor
progression, PAI-1 also promotes tumor growth and angiogenesis
on its own [36,37]. In this sense, a therapy that would attenuate
uPAR expression without promoting tumor growth would be
valuable. Since metastasis is the primary cause of death in cancer
patients, uPAR sensitivity to DBP-maf may represent an attractive
avenue for further study.
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